Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Austrian complex-study on dipropylacetate. Pediatric experiences]

Ch Groh, F W Rosenmayr

    Padiatrie Und Padologie
    |January 1, 1976
    PubMed
    Summary

    Dipropylacetat (Convulex) is effective for primary generalized epilepsies, including Lennox-Syndrome, with fewer side effects than standard anticonvulsants. It offers good therapeutic effects, especially in newly diagnosed patients, with a recommended dosage of 20-50 mg/kg/day for children.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    [Treatment result and treatment resistance in early childhood petit mal epilepsy].

    Padiatrie und Padologie·1981
    Same author

    [Borderline between antiepileptic and psychopharmacological drugs (author's transl)].

    Padiatrie und Padologie·1975
    Same author

    [Psychotic manifestations in childhood. III. Abnormal reactions to adventures (author's transl)].

    Padiatrie und Padologie·1975
    Same author

    [Immediate EEG changes produced by i.v. clonazepam medication--a new criterion for specific antiepileptic therapy (author's transl)].

    Wiener klinische Wochenschrift·1974
    Same author

    [Isolated petit mal status epilepticus. A new epilepsy syndrome characterised by paroxysmal behavioural disturbances (author's transl)].

    Deutsche medizinische Wochenschrift (1946)·1974
    Same author

    [Psychotic manifestations in children. I. Associated psychoses].

    Padiatrie und Padologie·1974

    Area of Science:

    • Neurology
    • Clinical Pharmacology

    Context:

    • Multicenter clinical trials are crucial for gathering reliable data efficiently.
    • Dipropylacetat (DPA) is an anticonvulsant medication used in epilepsy treatment.

    Purpose:

    • To evaluate the efficacy, safety, and optimal dosage of Dipropylacetat (Convulex) in a multicenter clinical trial.
    • To compare Convulex with standard anticonvulsants in treating various epilepsy types, particularly in treatment-naive patients.

    Summary:

    • The study demonstrated Dipropylacetat's (Convulex) good therapeutic effect in primary generalized epilepsies, irrespective of seizure type, and showed promising results in Lennox-Syndrome.
    • Convulex exhibited comparable efficacy to standard anticonvulsants but with significantly reduced side effects, notably less sedation, especially in previously untreated patients.
    • Therapeutic effects were observed earlier in treatment-naive individuals compared to those on prior medication. A recommended dosage of 20-50 mg/kg/day for children was established, with potential increases up to 120 mg/kg/day in some cases.

    Impact:

    • Provides evidence for Dipropylacetat (Convulex) as an effective and well-tolerated alternative for epilepsy management, particularly in specific syndromes and newly diagnosed cases.
    • Highlights the benefits of well-organized multicenter studies in rapidly obtaining reliable clinical information on antiepileptic drugs.
    • Suggests a favorable side-effect profile, especially reduced sedation, making Convulex a potentially valuable option for pediatric epilepsy treatment.

    Related Experiment Videos